EVOTEC SE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.52 EUR | -1.30% |
|
-2.46% | -55.26% |
| May. 06 | EVOTEC : Warburg Research reiterates its Buy rating | ZD |
| May. 03 | EVOTEC : RBC reiterates its Buy rating | ZD |
Presenter SpeechWerner Lanthaler (Executives)Good morning, good afternoon. Welcome to Evotec. ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâs health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Calendar
2024-05-14
- BofA Securities Health Care Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9.52
EUR
Average target price
21.99
EUR
Spread / Average Target
+130.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -55.26% | 1.82B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- EVT Stock
- News Evotec SE
- Transcript : Evotec SE - Special Call
